Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-negative, or basal-like, breast cancer cell lines. This phase 2 trial assessed efficacy and safety of single-agent dasa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2011-11, Vol.17 (21), p.6905-6913
Hauptverfasser:	FINN, Richard S, BENGALA, Carmelo, IBRAHIM, Nuhad, ROCHE, Henri, SPARANO, Joseph, STRAUSS, Lewis C, FAIRCHILD, Justin, SY, Oumar, GOLDSTEIN, Lori J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Dasatinib Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Pharmacology. Drug treatments Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Receptor, ErbB-2 - biosynthesis Receptors, Estrogen - biosynthesis Receptors, Progesterone - biosynthesis src-Family Kinases - antagonists & inhibitors src-Family Kinases - metabolism Thiazoles - adverse effects Thiazoles - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!